SCHEMBL2931988

SCHEMBL2931988

O=C(O)N1CCC(Cc2ccccc2)C1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 2/20 0.75
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
FAAH O00519 1/20 0.60
MGLL Q99685 1/20 0.58
SPR P35270 1/20 0.57
CYP2C9 P11712 3/20 0.57
CYP2C19 P33261 3/20 0.57
MAPK14 Q16539 3/20 0.57
HTR2B P41595 2/20 0.57
LMNA P02545 1/20 0.57
GAA P10253 1/20 0.57
TACR1 P25103 1/20 0.56
KCNH2 Q12809 1/20 0.56
HRH3 Q9Y5N1 1/20 0.56
ALDH1A1 P00352 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31324479 0.90 TACR3 (0.62) TACR3MEN1KMT2AFAAHSPR
SCHEMBL2636547 0.90 MEN1 (0.68) TACR3MEN1KMT2AFAAHMGLL
SCHEMBL18620100 0.87 TACR3 (0.71) TACR3MEN1KMT2AFAAHMGLL
SCHEMBL1761001 0.87 TACR3 (0.71) TACR3MEN1KMT2AFAAHMGLL
SCHEMBL21763292 0.87 TACR3 (0.71) TACR3MEN1KMT2AFAAHMGLL
SCHEMBL2930984 0.86 TACR3 (0.57) TACR3MEN1KMT2AFAAHSPR
SCHEMBL23365234 0.84 SPR (0.56) TACR3MEN1KMT2AFAAHSPR
SCHEMBL13738825 0.84 TACR3 (0.56) TACR3MEN1KMT2ASPRCYP2C9
SCHEMBL13738405 0.84 TACR3 (0.56) TACR3MEN1KMT2ASPRCYP2C9
SCHEMBL15608134 0.84 TACR3 (0.56) TACR3MEN1KMT2ASPRCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 EP claimed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 EP claimed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO claimed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US claimed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 EP disclosed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 EP disclosed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives ADORA2B, UTS2R, TBXA2R TACR3 1336/4885MEN1 4682/4885KMT2A 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.